Alnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan

October 6, 2016 7:39 AM EDT
Get Alerts ALNY Hot Sheet
Price: $38.96 -0.31%

Rating Summary:
    13 Buy, 7 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ALNY Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Chardan Capital Markets analyst Madhu Kumar cut the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $77.00 (from $115.00) after the company announced the discontinuation of the development of revusiran, a RNAi drug
which was in phase III trials targeting transthyretin (TTR), for the treatment of TTR familial amyloid cardiomyopathy
(TTR-FAC). Teh firm maintained a Buy rating.

Kumar commented, "FAC). The decision was, per Alnylam, based on a meeting of the data monitoring committee (DMC) for
ENDEAVOUR, revusiran's phase III trial, in which the DMC "informed the Company that the benefit-risk profile for
revusiran no longer supported continued dosing." The meeting was followed by Alnylam learning that, upon unblinding
ENDEAVOUR, there was "an imbalance of mortality in the revusiran arm as compared to placebo." Alnylam
emphasized that the discontinuation of revusiran had no impact on the company's other phase III asset, patisiran, a
second RNAi drug targeting TTR familial amyloid polyneuropathy (TTR-FAP) for which topline results are expected
mid-2017, or any of the additional RNAi therapies in development. Due to the loss of the revusiran franchise (NPV of
$34.68/share) and related financial effects, we lower our price target from $115/share to $77/share."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Chardan Capital Markets

Add Your Comment